News

1933 Industries Issues Final Reminder to 2024 Debenture Holders: December 22 Is the Deadline to Convert

VANCOUVER, BC / ACCESS Newswire / December 22, 2025 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF) issues…

3 hours ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist,…

3 hours ago

1933 Industries Achieves Positive Income in Q1 2026, Marking Third Consecutive Profitable Quarter

VANCOUVER, BC / ACCESS Newswire / December 22, 2025 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCID:TGIFF), a…

3 hours ago

PeopleOne Health Selected by Orlando Regional REALTOR® Association to Deliver First-of-Its-Kind Healthcare Solution for Realtors

Partnership to expand access to personalized primary care, including same-day appointments and mental health services, for more than 18,000 Central…

3 hours ago

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative…

3 hours ago

CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing,…

3 hours ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest…

3 hours ago

Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy

Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva…

3 hours ago

Vivos Inc Summarzes Preogress in its Animal Therapy Division

Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase…

3 hours ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE)…

3 hours ago